Periodic Reporting for period 2 - Bac3Gel (New generation of substrates to harness the full power of microorganisms)
Okres sprawozdawczy: 2024-07-01 do 2025-10-31
Microbiome research is a growing driver of innovation in healthcare, biotechnology, food systems, and sustainable bio-industries. However, its progress is limited by the lack of reliable and scalable in vitro tools capable of reproducing the complex environments in which many microorganisms naturally live. This challenge is particularly relevant for mucus-associated ecosystems in the human body, where many microorganisms remain difficult or impossible to culture using conventional laboratory methods.
The Bac3Gel project addressed this gap by developing and validating three-dimensional in vitro substrates that mimic key features of human mucus. By recreating native gradients of oxygen, nutrients, hydration, and mechanical properties, the Bac3Gel platform enables the stable growth of complex microbial communities under conditions that better reflect those found in vivo, allowing more physiologically relevant and reproducible microbiome studies.
The main objective of the project was to translate this mucus-mimicking technology from a laboratory-validated concept into market-ready products suitable for industrial and applied research. Through extensive technical validation in real-world research environments, the project demonstrated the robustness, scalability, and usability of the Bac3Gel platform.
By providing a ready-to-use in vitro solution, the project supports the adoption of non-animal testing methodologies, improves the predictive value of microbiome research, and accelerates the translation of microbiome science into industrial, regulatory, and healthcare applications. The outcomes benefit academic laboratories, contract research organisations, biotech SMEs, and industrial R&D teams, while contributing to European priorities on New Approach Methodologies, reduction of animal experimentation, and strengthened innovation capacity in biotechnology.
The Bac3Gel project addressed this gap by developing and validating three-dimensional in vitro substrates that mimic key features of human mucus. By recreating native gradients of oxygen, nutrients, hydration, and mechanical properties, the Bac3Gel platform enables the stable growth of complex microbial communities under conditions that better reflect those found in vivo, allowing more physiologically relevant and reproducible microbiome studies.
The main objective of the project was to translate this mucus-mimicking technology from a laboratory-validated concept into market-ready products suitable for industrial and applied research. Through extensive technical validation in real-world research environments, the project demonstrated the robustness, scalability, and usability of the Bac3Gel platform.
By providing a ready-to-use in vitro solution, the project supports the adoption of non-animal testing methodologies, improves the predictive value of microbiome research, and accelerates the translation of microbiome science into industrial, regulatory, and healthcare applications. The outcomes benefit academic laboratories, contract research organisations, biotech SMEs, and industrial R&D teams, while contributing to European priorities on New Approach Methodologies, reduction of animal experimentation, and strengthened innovation capacity in biotechnology.
Over the course of the project, Bac3Gel advanced from technology optimisation to validation in relevant industrial and applied research environments, reaching advanced technical readiness and4 market penetration. The work combined research and development, biological validation, robustness assessment under real-world conditions, and translation of technical results into deployable products informed by end-user feedback.
The project delivered a biomimetic three-dimensional in vitro mucus-based platform (i-Mu3Gel®, commercialised as Gut3Gel) with intrinsic physicochemical gradients, enabling the simultaneous support of aerobic and anaerobic microorganisms and the study of complex microbial interactions not accessible with conventional culture systems. The platform enabled reproducible cultivation of complex gut microbiota, sustaining up to approximately 90% of bacterial species present in the original inocula, including mucus-associated and hard-to-culture taxa.
Scientific validation using defined consortia and human-derived microbiota demonstrated sustained diversity, metabolic activity, and functional stability, exceeding the performance of standard in vitro approaches. The platform was further demonstrated as a non-animal testing tool, showing in vitro responses to dietary fibres and bioactive compounds consistent with trends reported in clinical studies.
Validation in multiple industrial testbeds confirmed compatibility with existing laboratory and industrial workflows, without the need for specialised equipment. These results supported market deployment, with customer feedback from initial use informing refinements in product format, usability, packaging, and documentation. In parallel, scalable and ready-to-use formats, including complementary bead-based configurations, were developed to support high-throughput screening and applied development.
Shelf-life and logistics studies demonstrated maintained sterility and functional performance for up to nine months under defined storage conditions. By project end, Bac3Gel had established a technically validated in vitro microbiome platform with demonstrated industrial relevance and market penetration, supported by experimental evidence and aggregated customer feedback, while preserving confidentiality of partner-specific data.
The project delivered a biomimetic three-dimensional in vitro mucus-based platform (i-Mu3Gel®, commercialised as Gut3Gel) with intrinsic physicochemical gradients, enabling the simultaneous support of aerobic and anaerobic microorganisms and the study of complex microbial interactions not accessible with conventional culture systems. The platform enabled reproducible cultivation of complex gut microbiota, sustaining up to approximately 90% of bacterial species present in the original inocula, including mucus-associated and hard-to-culture taxa.
Scientific validation using defined consortia and human-derived microbiota demonstrated sustained diversity, metabolic activity, and functional stability, exceeding the performance of standard in vitro approaches. The platform was further demonstrated as a non-animal testing tool, showing in vitro responses to dietary fibres and bioactive compounds consistent with trends reported in clinical studies.
Validation in multiple industrial testbeds confirmed compatibility with existing laboratory and industrial workflows, without the need for specialised equipment. These results supported market deployment, with customer feedback from initial use informing refinements in product format, usability, packaging, and documentation. In parallel, scalable and ready-to-use formats, including complementary bead-based configurations, were developed to support high-throughput screening and applied development.
Shelf-life and logistics studies demonstrated maintained sterility and functional performance for up to nine months under defined storage conditions. By project end, Bac3Gel had established a technically validated in vitro microbiome platform with demonstrated industrial relevance and market penetration, supported by experimental evidence and aggregated customer feedback, while preserving confidentiality of partner-specific data.
The results of the Bac3Gel project go beyond the state of the art in microbiology and in vitro modelling by delivering a biomimetic platform that combines structural realism, functional relevance, and practical usability. Unlike conventional culture systems based on homogeneous conditions, Bac3Gel enables controlled reproduction of key microenvironmental features required for microbiome stability and function.
Key advancements include:
- Biomimetic three-dimensional substrates with intrinsic gradients, enabling the simultaneous support of aerobic and anaerobic microorganisms and the study of complex microbial interactions not accessible with conventional in vitro methods.
- Reproducible cultivation of complex microbiota, including mucus-associated and hard-to-culture species, under controlled conditions, expanding the experimental toolbox available to researchers and industrial developers.
- Compatibility with existing laboratory and industrial infrastructures, allowing seamless integration into current workflows without the need for specialised equipment.
- Scalable, ready-to-use formats, supporting high-throughput screening, pilot-scale validation, and translation from research to applied development.
Together, these results position Bac3Gel as an enabling platform for microbiome research, microbiome-derived product development, food and supplement innovation, and sustainable bioproduction. Further uptake will be supported by continued industrial partnerships, regulatory and standardisation alignment, and access to scale-up and growth financing.
Key advancements include:
- Biomimetic three-dimensional substrates with intrinsic gradients, enabling the simultaneous support of aerobic and anaerobic microorganisms and the study of complex microbial interactions not accessible with conventional in vitro methods.
- Reproducible cultivation of complex microbiota, including mucus-associated and hard-to-culture species, under controlled conditions, expanding the experimental toolbox available to researchers and industrial developers.
- Compatibility with existing laboratory and industrial infrastructures, allowing seamless integration into current workflows without the need for specialised equipment.
- Scalable, ready-to-use formats, supporting high-throughput screening, pilot-scale validation, and translation from research to applied development.
Together, these results position Bac3Gel as an enabling platform for microbiome research, microbiome-derived product development, food and supplement innovation, and sustainable bioproduction. Further uptake will be supported by continued industrial partnerships, regulatory and standardisation alignment, and access to scale-up and growth financing.